Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:approves |
non-small cell lung cancer
urothelial carcinoma triple-negative breast cancer |
| gptkbp:associatedWith |
immunotherapy
|
| gptkbp:availableIn |
vials
|
| gptkbp:chemicalFormula |
IgG1
|
| gptkbp:clinicalTrials |
gptkb:IMvigor211
combination therapy Phase III monotherapy IMvigor130 KEYNOTE-689 IMvigor150 |
| gptkbp:contraindication |
hepatitis
autoimmune disease organ transplant pneumonitis colitis endocrinopathies active infection |
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:drugInterdiction |
immune checkpoint blockade
half-life 27 days |
| gptkbp:financial_aid |
24 hours at room temperature
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tecentriq
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:isUsedFor |
chemotherapy
targeted therapy |
| gptkbp:lastProduced |
gptkb:USA
gptkb:EU |
| gptkbp:mandates |
lung cancer
breast cancer advanced bladder cancer |
| gptkbp:marketedAs |
gptkb:Atezolizumab
|
| gptkbp:marketSegment |
available
|
| gptkbp:patentStatus |
patented
|
| gptkbp:patentType |
May 18, 2016
|
| gptkbp:researchFocus |
cancer immunotherapy
treatment resistance biomarker_identification |
| gptkbp:route |
IV
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea immune-mediated reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:PD-L1
|
| gptkbp:triggerType |
PD-L1_inhibitor
|